Atnahs Pharma Denmark ApS: Financial statements 2024
CVR: 36699051
Source: annual report 2024, Danish Business Authority
01/04/2023 – 31/03/2024
Atnahs Pharma Denmark ApS (CVR 36699051) has filed annual accounts for 2024. In 2024, the company reported revenue of EUR 91,292,078 and a net result of EUR 20,450 compared with DKK 14,720,135 the year before. That is a decrease of 82.3% compared with the year before. The profit margin was 0%. Equity in the 2024 report amounted to EUR 2,015,738. The solvency ratio was 3%.
- Revenue
- EUR 91,292,078
- Gross Profit
- EUR 925,366
- Profit/Loss
- EUR 20,450
- Equity
- EUR 2,015,738
- Total Assets
- EUR 66,994,716
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 91.3M EUR | 925K EUR | 20K EUR | 2M EUR | - |
| 2023 | 517.2M | -19.4M | 14.7M | 14.9M | - |
| 2022 | - | 9.8M | 3.6M | 142K | - |
| 2021 | - | 5.1M | 275K | -3.5M | - |
| 2020 | - | -1.3M | -1.4M | -3.8M | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningAbout Atnahs Pharma Denmark ApS
Atnahs Pharma Denmark ApS is a Danish company of the type Anpartsselskab based in København S, founded in 2015. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named Pharmamentum ApS. The management consists of Christoph Michael Habereder. The board consists of Mohammad Muqtadir Samy (chair), Christoph Michael Habereder and Twan Johannes Anna Nouwen. The company is owned by Atnahs Pharma UK Limited. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported revenue of EUR 52,583,756 and a net result of EUR 12,487 compared with DKK 47,843 the year before. Equity in the 2026 report amounted to EUR 2,094,136.